Andrew Technologies, LLC has received FDA 510 (k) clearance for the commercially manufactured version of the HydraSolve™ Lipoplasty System which it claims obviates the need for physicians to hack away at that stubborn lard.
According to the International Society of Aesthetic Plastic Surgery over 2 million liposuction procedures are conducted annually across the globe, a figure large enough (pardon the pun) to put you off your Christmas dinner… or represent a market opportunity…or both.
Andrew Technologies says it will begin commercialisation with a selective launch to pre-identified expert plastic surgeons in the United States in early 2013. This “soft launch” will generate clinical data that will be used to quantify the benefits of HydraSolve™ to be used in future communication with surgeons and with patients seeking aesthetic body contouring. The company intends to expand the launch nationally by mid-2013 and to begin rest of world distribution in 2014.
“The advantages of HydraSolve™ offer the potential for Andrew Technologies to capture a significant share of the market; and to potentially expand the overall demand for liposuction, given its excellent consumer resonance and gentle effect on patients,” stated Tom Albright , CEO of Andrew Technologies.
According to Dr. Mark Andrew, co-inventor and Chief Scientific Officer of Andrew technologies; “HydraSolve™ is the first non-cutting liposuction device, it offers a target-tissue specific method to remove fat tissue and only fat tissue so that collateral damage to non-targeted tissues is reduced and minimized, with the intention of shortening the patient’s post-op recovery period and minimizing his or her pain, swelling and bruising. Additionally, HydraSolve™ provides excellent control and precision in removing fat tissue for surgeons, and it also reduces their physical exertion.”
Source: Andrew Technologies, LLC, PR Newswire